<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Sodium citrate and citric acid (oral solution): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Sodium citrate and citric acid (oral solution): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Sodium citrate and citric acid (oral solution): Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11426" href="/d/html/11426.html" rel="external">see "Sodium citrate and citric acid (oral solution): Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="16774" href="/d/html/16774.html" rel="external">see "Sodium citrate and citric acid (oral solution): Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F221727"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Cytra-2;</li>
<li>Oracit</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52914214"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>PMS-Dicitrate</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F221741"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Alkalinizing Agent, Oral</li></ul></div>
<div class="block doa drugH1Div" id="F221731"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0630d101-11f0-4e10-a074-78688ff505ad">Acidosis or systemic alkalization</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acidosis or systemic alkalization:</b>
<b>Oral:</b> 10 to 30 mL 4 times daily.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b9e2fd80-308d-4eb0-a497-00b0397cb8b3">Aspiration prophylaxis in patients undergoing anesthesia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Aspiration prophylaxis in patients undergoing anesthesia (off-label use): Note: </b>May be considered in patients at high risk for aspiration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26580836','lexi-content-ref-berkow.2019','lexi-content-ref-hagberg.2019','lexi-content-ref-21673588','lexi-content-ref-20562638','lexi-content-ref-11692973']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26580836','lexi-content-ref-berkow.2019','lexi-content-ref-hagberg.2019','lexi-content-ref-21673588','lexi-content-ref-20562638','lexi-content-ref-11692973'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 30 mL given immediately before surgery in conjunction with other appropriate agents (eg, IV H<sub>2</sub> antagonist and/or IV metoclopramide given ~30 to 90 minutes prior to surgery) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Abir.2019','lexi-content-ref-28045707','lexi-content-ref-berkow.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Abir.2019','lexi-content-ref-28045707','lexi-content-ref-berkow.2019'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="01b75c4a-f57f-4eb8-a65c-f00bed8e6e21">Gastric acid buffer</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Gastric acid buffer: Oral:</b> 15 mL as a single dose.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c2780b49-1e3b-494f-9033-aceaae2ba8de">Metabolic acidosis in patients with chronic kidney disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Metabolic acidosis in patients with chronic kidney disease: </b>
<b>Note:</b> KDIGO guidelines suggest oral replacement when plasma HCO3- concentrations are &lt;22 mEq/L (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-KDIGO.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-KDIGO.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral (off-label dose):</b> Initial: 15 to 22.5 mL/day in 2 to 3 divided doses; titrate to normal serum bicarbonate concentrations (eg, 23 to 29 mEq/L although a more targeted range of 24 to 26 mEq/L for patients with non–dialysis-dependent chronic kidney disease [CKD] has been suggested by observational studies (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25896890','lexi-content-ref-31036389']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25896890','lexi-content-ref-31036389'])">Ref</a></span>)) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23932089','lexi-content-ref-KDIGO.1','lexi-content-ref-19015169','lexi-content-ref-26776539']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23932089','lexi-content-ref-KDIGO.1','lexi-content-ref-19015169','lexi-content-ref-26776539'])">Ref</a></span>). Avoid exceeding serum bicarbonate concentrations &gt;29 mEq/L since this has been associated with increased mortality in patients with CKD (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19015169','lexi-content-ref-31036389']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19015169','lexi-content-ref-31036389'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990969"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Contains sodium; use with caution, especially in patients with concomitant hypertension, heart failure, or volume overload (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23932089']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23932089'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b> No dosage adjustment necessary for any degree of kidney dysfunction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988337"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling; use with caution.</p></div>
<div class="block doe drugH1Div" id="F221732"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F221737"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="16774" href="/d/html/16774.html" rel="external">see "Sodium citrate and citric acid (oral solution): Pediatric drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Individualize dose as determined by disease and patient-specific targets. 1 mL of oral solution contains 1 mEq of bicarbonate and 1 mEq of sodium.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="420e6080-5bea-45b8-8caa-8eb5b9230eb4">Renal tubular acidosis, distal</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Renal tubular acidosis (RTA), distal (Type 1): </b>Limited data available: <b>Note:</b> Dose requirements may vary with age. Infants, Children, and Adolescents: Oral: Usual dose: 2 to 4 mEq bicarbonate/kg/<b>day</b> (2 to 4 mL/kg/<b>day</b>) in divided doses; reported range: 1 to 7 mEq bicarbonate/kg/<b>day</b>; adjust dose to maintain target serum CO<sub>2 </sub>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11483854','lexi-content-ref-Kliegman.2016','lexi-content-ref-12138150','lexi-content-ref-3777038']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11483854','lexi-content-ref-Kliegman.2016','lexi-content-ref-12138150','lexi-content-ref-3777038'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="597569cd-5d10-49b1-bf8a-8dfbb0d927fd">Renal tubular acidosis, proximal</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Renal tubular acidosis (RTA), proximal (Type 2):</b> Limited data available: <b>Note:</b> Dose requirements may vary with age; for Type 2 RTA, bicarbonate doses are higher than those required for other types of RTA. Infants, Children, and Adolescents: Oral: Usual range: 10 to 20 mEq bicarbonate/kg/<b>day</b> in divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11483854','lexi-content-ref-Kliegman.2016','lexi-content-ref-12138150']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11483854','lexi-content-ref-Kliegman.2016','lexi-content-ref-12138150'])">Ref</a></span>); <b>Note:</b> May be used in combination with potassium citrate formulations to meet bicarbonate requirement.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="22e8cf10-7078-43fd-ab81-1a8a524d3f14">Systemic alkalinization; chronic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Systemic alkalinization; chronic:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Volume-based dosing: Children ≥2 years and Adolescents: Oral: 5 to 15 mL (5 to 15 mEq bicarbonate) per dose after meals and at bedtime.</p>
<p style="text-indent:-2em;margin-left:4em;">Weight-based dosing (mEq bicarbonate/kg): Limited data available: Infants, Children, and Adolescents: Oral: 2 to 3 mEq bicarbonate/kg/<b>day</b> (2 to 3 mL/kg/<b>day</b>) in 3 to 4 divided doses; adjust dose to targeted serum bicarbonate levels; typical adult doses do not exceed 30 mEq/dose (30 mL/dose) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Gal.2007']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Gal.2007'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51160095"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling; use is contraindicated in patients with anuria, severe renal impairment, oliguria, or azotemia.</p></div>
<div class="block dohp drugH1Div" id="F51160096"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling; use with caution.</p></div>
<div class="block adr drugH1Div" id="F221706"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Frequency not defined. Generally well tolerated with normal renal function.</p>
<p style="text-indent:-2em;margin-left:2em;">Central nervous system: Tetany</p>
<p style="text-indent:-2em;margin-left:2em;">Endocrine &amp; metabolic: Metabolic alkalosis</p>
<p style="text-indent:-2em;margin-left:2em;">Gastrointestinal: Diarrhea, nausea, vomiting</p></div>
<div class="block coi drugH1Div" id="F221718"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to sodium citrate, citric acid, or any component of the formulation; untreated Addison disease; adynamia episodica hereditaria; acute dehydration; heat cramp; severe myocardial damage; sodium-restricted diet. <b>Note:</b> Although the manufacturer's labeling states use in severe renal impairment, oliguria, azotemia, anuria, or hyperkalemia is contraindicated, use in these patients may be considered under close medical supervision.</p></div>
<div class="block war drugH1Div" id="F221703"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Use with caution in patients with heart failure or hypertension; contains sodium.</p>
<p style="text-indent:-2em;margin-left:4em;">• Edema: Use with caution in patients with peripheral or pulmonary edema; contains sodium.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic failure; conversion to bicarbonate may be impaired.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment; contains sodium.</p>
<p style="text-indent:-2em;margin-left:4em;">• Severely ill: Use with caution in patients who are severely ill; conversion to bicarbonate may be impaired.</p>
<p style="text-indent:-2em;margin-left:4em;">• Shock: Use with caution in patients who are in shock; conversion to bicarbonate may be impaired.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP ["Inactive" 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates. See manufacturer’s labeling.</p>
<p style="text-indent:-2em;margin-left:4em;">• Propylene glycol: Some dosage forms may contain propylene glycol; large amounts are potentially toxic and have been associated hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Zar 2007).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Administration: Dilute with water to minimize GI injury; administer after meals to minimize saline laxative effect.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878634"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Some dosage forms may contain propylene glycol; in neonates large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3,000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; toxicities have also been reported in children and adults including hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Shehab 2009).</p></div>
<div class="block dosfc drugH1Div" id="F21963671"><span class="drugH1">Dosage Forms Considerations</span>
<p style="text-indent:0em;display:inline">Each mL provides 1 mEq sodium, and is equivalent to 1 mEq bicarbonate</p></div>
<div class="block foc drugH1Div" id="F221713"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;">Solution, oral:</p>
<p style="text-indent:-2em;margin-left:4em;">Cytra-2: Sodium citrate 500 mg and citric acid 334 mg per 5 mL (480 mL) [alcohol free, dye free, sugar free; contains propylene glycol and sodium benzoate; grape flavor; contains sodium 1 mEq/mL equivalent to bicarbonate 1 mEq /mL]</p>
<p style="text-indent:-2em;margin-left:4em;">Oracit: Sodium citrate 490 mg and citric acid 640 mg per 5 mL (15 mL, 30 mL, 500 mL) [contains sodium 1 mEq/mL equivalent to bicarbonate 1 mEq /mL]</p>
<p style="text-indent:-2em;margin-left:4em;">Generic: Sodium citrate 500 mg and citric acid 334 mg per 5 mL (15 mL, 30 mL, 480 mL)</p></div>
<div class="block geq drugH1Div" id="F221700"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F221719"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Oracit Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">490-640 mg/5 mL (per mL): $0.25</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Sod Citrate-Citric Acid Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500-334 mg/5 mL (per mL): $0.32 - $0.34</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F221715"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Administer after meals. When used for acidosis/systemic alkalinization, administer after meals and at bedtime.</p></div>
<div class="block admp drugH1Div" id="F52613864"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Shake well before use. Dose must be diluted prior to administration; administer after meals and at bedtime to avoid saline laxative effect; chilling solution prior to dosing helps to enhance palatability. </p></div>
<div class="block use drugH1Div" id="F221714"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Acidosis:</b> Treatment of metabolic acidosis or acidosis in certain renal tubular disorders.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Gastric acid buffer:</b> Buffer agent to neutralize gastric acidity.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Systemic alkalinizer:</b> Alkalinizing agent in conditions where long-term maintenance of alkaline urine is desirable.</p></div>
<div class="block off-label drugH1Div" id="F53996486"><span class="drugH1">Use: Off-Label: Adult</span><p>Aspiration prophylaxis in patients undergoing anesthesia</p></div>
<div class="block mst drugH1Div" id="F7914136"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Bicitra may be confused with Polycitra</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13300056"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F221708"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alpha-/Beta-Agonists (Indirect-Acting): Alkalinizing Agents may increase the serum concentration of Alpha-/Beta-Agonists (Indirect-Acting). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aluminum Hydroxide: Citric Acid Derivatives may increase the absorption of Aluminum Hydroxide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amantadine: Alkalinizing Agents may increase the serum concentration of Amantadine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amphetamines: Alkalinizing Agents may decrease the excretion of Amphetamines.  Management: Consider alternatives to using amphetamines and alkalinizing agents in combination. If these agents must be used together, patients should be monitored closely for excessive amphetamine effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flecainide: Alkalinizing Agents may decrease the excretion of Flecainide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mecamylamine: Alkalinizing Agents may increase the serum concentration of Mecamylamine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Memantine: Alkalinizing Agents may increase the serum concentration of Memantine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QuiNIDine: Alkalinizing Agents may increase the serum concentration of QuiNIDine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QuiNINE: Alkalinizing Agents may increase the serum concentration of QuiNINE. <i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F221720"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Use caution with toxemia of pregnancy.</p></div>
<div class="block dic drugH1Div" id="F221721"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Take after meals to minimize laxative effect.</p></div>
<div class="block mop drugH1Div" id="F13246577"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Serum creatinine, BUN, LFTs, serum bicarbonate and urinary pH at baseline and as clinically indicated during therapy; periodic serum electrolytes (especially bicarbonate) in patients with renal disease.</p></div>
<div class="block rer drugH1Div" id="F13246579"><span class="drugH1">Reference Range</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Reference ranges may vary depending on the laboratory</p>
<p style="text-indent:-2em;margin-left:2em;">Urinary pH: 4.6 to 8.0</p></div>
<div class="block phk drugH1Div" id="F221717"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: ≥95% via hepatic oxidation to bicarbonate; may be impaired in patients with hepatic failure, shock, or severe illness</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Urine (&lt;5% as sodium citrate)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F58197751"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Carmicide</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Virtrate 2</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Pneucid</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-Abir.2019">
<a name="Abir.2019"></a>Abir G, Carvalho B. Anesthesia for nondelivery obstetric procedures. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 21, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11487763">
<a name="11487763"></a>Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-citrate-and-citric-acid-oral-solution-drug-information/abstract-text/11487763/pubmed" id="11487763" target="_blank">11487763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26580836">
<a name="26580836"></a>American Society of Anesthesiologists. Practice guidelines for obstetric anesthesia: an updated report by the American Society of Anesthesiologists Task Force on Obstetric Anesthesia and the Society for Obstetric Anesthesia and Perinatology. <i>Anesthesiology</i>. 2016;124(2):270-300. doi:10.1097/ALN.0000000000000935<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-citrate-and-citric-acid-oral-solution-drug-information/abstract-text/26580836/pubmed" id="26580836" target="_blank">26580836</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28045707">
<a name="28045707"></a>American Society of Anesthesiologists. Practice guidelines for preoperative fasting and the use of pharmacologic agents to reduce the risk of pulmonary aspiration: application to healthy patients undergoing elective procedures: an updated report by the American Society of Anesthesiologists Task Force on Preoperative Fasting and the Use of Pharmacologic Agents to Reduce the Risk of Pulmonary Aspiration. <i>Anesthesiology</i>. 2017;126(3):376-393. doi:10.1097/ALN.0000000000001452<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-citrate-and-citric-acid-oral-solution-drug-information/abstract-text/28045707/pubmed" id="28045707" target="_blank">28045707</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-berkow.2019">
<a name="berkow.2019"></a>Berkow L. Rapid sequence induction and intubation (RSII) for anesthesia. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 29, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6810084">
<a name="6810084"></a>Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-citrate-and-citric-acid-oral-solution-drug-information/abstract-text/6810084/pubmed" id="6810084" target="_blank">6810084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11483854">
<a name="11483854"></a>Chan JC, Scheinman JI, Roth KS. Consultation with the specialist: renal tubular acidosis. <i>Pediatr Rev</i>. 2001;22(8):277-287.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-citrate-and-citric-acid-oral-solution-drug-information/abstract-text/11483854/pubmed" id="11483854" target="_blank">11483854</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23932089">
<a name="23932089"></a>Chen W, Abramowitz MK. Treatment of metabolic acidosis in patients with CKD. <i>Am J Kidney Dis</i>. 2014;63(2):311-317. doi:10.1053/j.ajkd.2013.06.017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-citrate-and-citric-acid-oral-solution-drug-information/abstract-text/23932089/pubmed" id="23932089" target="_blank">23932089</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cytra.1">
<a name="Cytra.1"></a>Cytra-2 Oral Solution (sodium citrate and citric acid) [package insert]. Morristown, NJ: Cypress Pharmaceutical, Inc; November 2014.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25896890">
<a name="25896890"></a>Dobre M, Yang W, Pan Q, et al; CRIC Study Investigators. Persistent high serum bicarbonate and the risk of heart failure in patients with chronic kidney disease (CKD): a report from the Chronic Renal Insufficiency Cohort (CRIC) study. <i>J Am Heart Assoc</i>. 2015;4(4):e001599. doi:10.1161/JAHA.114.001599<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-citrate-and-citric-acid-oral-solution-drug-information/abstract-text/25896890/pubmed" id="25896890" target="_blank">25896890</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Eichenwald.2017">
<a name="Eichenwald.2017"></a>Eichenwald EC. <i>Manual of Neonatal Care</i>. 8th edition. Philadelphia, PA: Lippincott Williams &amp; Wilkins; 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Gal.2007">
<a name="Gal.2007"></a>Gal P, Reed M. Medications. In: Kliegman RM, Behrman RE, Jenson HB, et al, eds. <i>Nelson Textbook of Pediatrics</i>. 18th ed. Philadelphia, PA: Saunders Elsevier; 2007: 2955-2999.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-hagberg.2019">
<a name="hagberg.2019"></a>Hagberg CA, Artime C. Flexible scope intubation for anesthesia. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 18, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-citrate-and-citric-acid-oral-solution-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-kellner.2019">
<a name="kellner.2019"></a>Kellner C. Technique for performing electroconvulsive therapy (ECT) in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 6, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-KDIGO.1">
<a name="KDIGO.1"></a>Kidney Disease Improving Global Outcomes (KDIGO). 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. <i>Kidney Int Suppl</i>. 2013;3(suppl 1):1-150. http://www.kidney-international.org.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kliegman.2016">
<a name="Kliegman.2016"></a>Kliegman RM, Stanton BMD, St. Geme J, Schor NF, eds. <i>Nelson Textbook of Pediatrics</i>. 20th ed. Philadelphia, PA: Saunders Elsevier; 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19015169">
<a name="19015169"></a>Kovesdy CP, Anderson JE, Kalantar-Zadeh K. Association of serum bicarbonate levels with mortality in patients with non-dialysis-dependent CKD. <i>Nephrol Dial Transplant</i>. 2009;24(4):1232-1237. doi:10.1093/ndt/gfn633<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-citrate-and-citric-acid-oral-solution-drug-information/abstract-text/19015169/pubmed" id="19015169" target="_blank">19015169</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21673588">
<a name="21673588"></a>Lovas A, Almos PZ, Peto Z, Must A, Szatmár H. Anesthesia for electroconvulsive therapy in early pregnancy. <i>J ECT</i>. 2011;27(4):328-330. doi: 10.1097/YCT.0b013e318213cd00.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-citrate-and-citric-acid-oral-solution-drug-information/abstract-text/21673588/pubmed" id="21673588" target="_blank">21673588</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6377973">
<a name="6377973"></a>Manchikanti L, Marrero TC, Roush JR. Preanesthetic cimetidine and metoclopramide for acid aspiration prophylaxis in elective surgery. <i>Anesthesiology</i>. 1984;61(1):48-54.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-citrate-and-citric-acid-oral-solution-drug-information/abstract-text/6377973/pubmed" id="6377973" target="_blank">6377973</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-nixon.2019">
<a name="nixon.2019"></a>Nixon H, Leffert L. Anesthesia for cesarean delivery. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed August 16, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7148360">
<a name="7148360"></a>Olsson GL, Hallén B. Pharmacological evacuation of the stomach with metoclopramide. <i>Acta Anaesthesiol Scand</i>. 1982;26(5):417-420. doi: 10.1111/j.1399-6576.1982.tb01791.x.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-citrate-and-citric-acid-oral-solution-drug-information/abstract-text/7148360/pubmed" id="7148360" target="_blank">7148360</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Oracit.1">
<a name="Oracit.1"></a>Oracit [package insert]. Farmville, NC: CMP Pharma; July 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20562638">
<a name="20562638"></a>O'Reardon JP, Cristancho MA, von Andreae CV, Cristancho P, Weiss D. Acute and maintenance electroconvulsive therapy for treatment of severe major depression during the second and third trimesters of pregnancy with infant follow-up to 18 months: case report and review of the literature. <i>J ECT</i>. 2011;27(1):e23-e26. doi:10.1097/YCT.0b013e3181e63160<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-citrate-and-citric-acid-oral-solution-drug-information/abstract-text/20562638/pubmed" id="20562638" target="_blank">20562638</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11692973">
<a name="11692973"></a>Rabheru K. The use of electroconvulsive therapy in special patient populations. <i>Can J Psychiatry</i>. 2001;46(8):710-719. doi:10.1177/070674370104600803<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-citrate-and-citric-acid-oral-solution-drug-information/abstract-text/11692973/pubmed" id="11692973" target="_blank">11692973</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26776539">
<a name="26776539"></a>Raphael KL. Approach to the treatment of chronic metabolic acidosis in CKD. <i>Am J Kidney Dis</i>. 2016;67(4):696-702. doi:10.1053/j.ajkd.2015.12.016<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-citrate-and-citric-acid-oral-solution-drug-information/abstract-text/26776539/pubmed" id="26776539" target="_blank">26776539</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31036389">
<a name="31036389"></a>Raphael KL. Metabolic acidosis in CKD: core curriculum 2019. <i>Am J Kidney Dis</i>. 2019;74(2):263-275. doi:10.1053/j.ajkd.2019.01.036<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-citrate-and-citric-acid-oral-solution-drug-information/abstract-text/31036389/pubmed" id="31036389" target="_blank">31036389</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12138150">
<a name="12138150"></a>Rodríguez Soriano J. Renal tubular acidosis: the clinical entity. <i>J Am Soc Nephrol</i>. 2002;13(8):2160-2170.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-citrate-and-citric-acid-oral-solution-drug-information/abstract-text/12138150/pubmed" id="12138150" target="_blank">12138150</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3777038">
<a name="3777038"></a>Santos F, Chan JC. Renal tubular acidosis in children. Diagnosis, treatment and prognosis. <i>Am J Nephrol</i>. 1986;6(4):289-295.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-citrate-and-citric-acid-oral-solution-drug-information/abstract-text/3777038/pubmed" id="3777038" target="_blank">3777038</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19188870">
<a name="19188870"></a>Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. <i>Pediatr Crit Care Med</i>. 2009;10(2):256-259.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-citrate-and-citric-acid-oral-solution-drug-information/abstract-text/19188870/pubmed" id="19188870" target="_blank">19188870</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8694150">
<a name="8694150"></a>Stuart JC, Kan AF, Rowbottom SJ, Yau G, Gin T. Acid aspiration prophylaxis for emergency Caesarean section. <i>Anaesthesia</i>. 1996;51(5):415-421. doi: 10.1111/j.1365-2044.1996.tb07782.x.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-citrate-and-citric-acid-oral-solution-drug-information/abstract-text/8694150/pubmed" id="8694150" target="_blank">8694150</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17555487">
<a name="17555487"></a>Zar T, Graeber C, Perazella MA. Recognition, treatment, and prevention of propylene glycol toxicity. <i>Semin Dial</i>. 2007;20(3):217-219.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-citrate-and-citric-acid-oral-solution-drug-information/abstract-text/17555487/pubmed" id="17555487" target="_blank">17555487</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9930 Version 137.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
